Ophthalmology

Zografos L, Rivero-Ferrer E, Abramsky S, Lou J, Davenport E, Wolin D. Evaluation of the physician education component of the ozurdex risk management plan. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.


BACKGROUND: In 2014, a survey was conducted to evaluate physician understanding of educational materials (Injector’s guide and patient’s guide) developed as part of the risk management plan (RMP) for Ozurdex. The educational materials were revised according to regulatory requirements and were redistributed beginning in 2014.

Chen E, Looman M, Laouri M, Gallagher M, Van Nuys K, Lakdawalla D, Fortuny J. Burden of illness of diabetic macular edema: literature review. Curr Med Res Opin. 2010 Jul;26(7):1587-97. doi: 10.1185/03007995.2010.482503 PMID 20429823


OBJECTIVE: To provide an overview of the literature on the burden of diabetic macular edema (DME) in the United States and selected European countries.

Zlateva GP, Javitt JC, Earnshaw SR, Pliel AM, Graham CN, Brogan AJ, Shah S, Adamis AP. Cost-effectiveness model for age-related macular degeneration: comparing early and late Macugen® treatment. Poster presented at the 2006 EURETINA Congress; May 21, 2006. Lisbon, Portugal. Previously presented at the 2005 ISPOR 8th Annual European Congress.


Samuelson T, Singh IP, Katz LJ, Falvey H, Odom D, McSorley D. Effect of iStent inject trabecular micro-bypass on patient-reported outcomes for those with open-angle glaucoma and coexisting cataracts. Poster presented at the ISPOR 2019 European Conference; November 6, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).


OBJECTIVES: To conduct an exploratory analysis comparing cataract surgery plus implantation of the trabecular micro-bypass stent (iStent inject) versus cataract surgery alone in patient-reported outcome (PRO) scores from the Vision Function Questionnaire (VFQ-25) and the Ocular Surface Disease Index (OSDI) by key baseline characteristics.

Zografos LJ, Andrews E, Wolin DL, Calingaert B, Davenport E, Hollis KA, Djokanovic N, Racanelli VS, Petraro P, Vassilev ZP. Evaluation of physician knowledge of the key safety information for aflibercept in Canada: evaluation of risk-minimization measures. Pharmaceut Med. 2019 Jun;33(3):235-46. doi: 10.1007/s40290-019-00278-z


BACKGROUND: As part of the risk-management plan (RMP) for aflibercept, materials have been developed to educate physicians in Canada on the key safety information and safe use for aflibercept.

Zografos LJ, Andrews E, Wolin DL, Calingaert B, Davenport EK, Hollis KA, Schmidt-Ott UM, Petraro P, Vassilev ZP. Physician and patient knowledge of safety and safe use information for aflibercept in Europe: evaluation of risk-minimization measures. Pharmaceut Med. 2019 Jun;33(3):219-33. doi: 10.1007/s40290-019-00279-y


BACKGROUND: As part of the risk-management plan for aflibercept in the European Union, materials have been developed to educate physicians and patients in Europe on the safe use of aflibercept.

Chambers TM, Agopian AJ, Lewis RA, Langlois PH, Danysh HE, Weber KA, Shaw GM, Mitchell LE, Lupo PJ. Epidemiology of anophthalmia and microphthalmia: prevalence and patterns in Texas, 1999-2009. Am J Med Genet A. 2018 Sep;176(9):1810-8. doi: 10.1002/ajmg.a.40352


Yuan BG, Tham VM, Browne EN, Weinrib R, Borkar DS, Parker JV, Uchida A, Vinoya AC, Acharya NR. Association between smoking and uveitis: results from the Pacific Ocular Inflammation study. Ophthalmology. 2015 Jun;122(6):1257-61. doi: 10.1016/j.ophtha.2015.02.03


PURPOSE: To assess whether cigarette smoking is associated with the development of uveitis in a population-based setting.

DESIGN: Retrospective, population-based, case-control study.

Oldenburg CE, Keenan JD, Cevallos V, Chan MF, Acharya NR, Gaynor BD, McLeod SD, Esterberg EJ, Porco TC, Lietman TM. Microbiological cure times in acanthamoeba keratitis. Eye (Lond). 2011 Sep;25(9):1155-60. doi: 10.1038/eye.2011.126


AIMS: The purpose of this study was to estimate the duration of treatment necessary for sequential acanthamoeba laboratory tests from corneal scrapings to become negative, and to assess predictors that affect this duration period.

Oldenburg CE, Sy A, Srinivasan M, Toutain-Kidd CM, Mascarenhas J, Ravindran M, Rajaraman R, Esterberg EJ, Chidambaram JD, Acharya NR, Lietman TM, Zegans ME. Pre-existing blindness in a cohort of patients with bacterial keratitis. Br J Ophthalmol. 2011 Dec;95(11):1612-3. doi: 10.1136/bjophthalmol-2011-300270.


Abstract not available at this time.

Subscribe to Ophthalmology

How Can We Help You?